Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are limited, with significant inter-individual variability.
• Polymorphisms in genes affecting drug pharmacokinetics and pharmacodynamics contribute to treatment efficacy variations.
• The nucleotide excision repair (NER) pathway is crucial for repairing DNA damage from chemotherapy, and its gene polymorphisms can influence cancer outcomes.

Purpose of the Study:

• To investigate the role of the NER pathway in STS.
• To identify associations between NER gene polymorphisms and treatment response, toxicity, or relapse in STS patients.
• To characterize the NER pathway in STS using molecular and genetic approaches.

Main Methods:

• DNA extraction and genotyping using SNP assay in STS patients.
• RNA extraction and quantitative real-time reverse transcription PCR (qPCR).
• Molecular dynamics simulations to analyze NER pathway components.

Main Results:

• A significant deregulation of the NER pathway was observed in the studied STS cohort.
• The study describes the effect of SNP rs1047768 in the ERCC5 structure, suggesting a role in modulating single-stranded DNA (ssDNA) binding.
• A correlation between a specific genotype profile of ERCC genes and NER pathway proficiency in STS was evidenced for the first time.

Conclusions:

• The NER pathway is deregulated in soft tissue sarcoma.
• Specific ERCC gene polymorphisms, like rs1047768 in ERCC5, may influence NER pathway function and potentially impact STS treatment.
• Genotyping ERCC genes could offer insights into NER pathway proficiency and treatment response in STS patients.